88. in vitro clot-lysis in the presence of cultured human umbilical vein endothelial cells, experiences in diabetes mellitus and liver cirrhosis

M. Udvardy, E. Posan, J. Hársfalvi, M. Kaplar, P. Batar, I. Altorjay

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In vitro plasma clot-lysis tests might carry some relevant information in vivo fibrinolysis, especially as an indicator of fibrinolytic inhibitors. In vitro clot-lysis experiments, induced by thrombin/tPA mixtures were performed, utilising a microplate light-scattering assessment method. The tests were repeated using the same plasma samples in each patients/controls in a microplate, which was covered by cultured endothelial-cell monolayer (umbilical vein, HUVEC). Clot lysis speed proved to be 1.5-2.0 times slower with HUVEC milieu in the control group (n=79). In insulin dependent diabetes mellitus (n=18) the same inhibition induced by HUVEC was observed, whereas in non-insulin dependent diabetics (n=36) the inhibition proved to be significantly weaker than in the controls. It is probably due to the elevated circulating PAI-1 levels in this type of diabetes. In the cirrhotic patients (p=41) this inhibition was stronger and resulted in a 5-fold reduction of lysis speed. Our results suggest, that cirrhotic plasma is able to accelerate the release of fibrinolytic inhibitors from HUVEC, which phenomenon may also contribute to the complex alterations of fibrinolysis in cirrhotic patients. In vitro plasma clot-lysis, performed in the presence or absence of HUVEC may give further information on fibrinolysis in a variety of clinical conditions.

Original languageEnglish
Pages (from-to)27
Number of pages1
JournalFibrinolysis
Volume10
Issue numberSUPPL. 1
Publication statusPublished - 1996

Fingerprint

Human Umbilical Vein Endothelial Cells
Liver Cirrhosis
Diabetes Mellitus
Fibrinolysis
Umbilical Veins
Plasminogen Activator Inhibitor 1
Thrombin
Cultured Cells
Endothelial Cells
Light
Control Groups
In Vitro Techniques

ASJC Scopus subject areas

  • Hematology

Cite this

@article{c4715a3a902748318c480350bef2d796,
title = "88. in vitro clot-lysis in the presence of cultured human umbilical vein endothelial cells, experiences in diabetes mellitus and liver cirrhosis",
abstract = "In vitro plasma clot-lysis tests might carry some relevant information in vivo fibrinolysis, especially as an indicator of fibrinolytic inhibitors. In vitro clot-lysis experiments, induced by thrombin/tPA mixtures were performed, utilising a microplate light-scattering assessment method. The tests were repeated using the same plasma samples in each patients/controls in a microplate, which was covered by cultured endothelial-cell monolayer (umbilical vein, HUVEC). Clot lysis speed proved to be 1.5-2.0 times slower with HUVEC milieu in the control group (n=79). In insulin dependent diabetes mellitus (n=18) the same inhibition induced by HUVEC was observed, whereas in non-insulin dependent diabetics (n=36) the inhibition proved to be significantly weaker than in the controls. It is probably due to the elevated circulating PAI-1 levels in this type of diabetes. In the cirrhotic patients (p=41) this inhibition was stronger and resulted in a 5-fold reduction of lysis speed. Our results suggest, that cirrhotic plasma is able to accelerate the release of fibrinolytic inhibitors from HUVEC, which phenomenon may also contribute to the complex alterations of fibrinolysis in cirrhotic patients. In vitro plasma clot-lysis, performed in the presence or absence of HUVEC may give further information on fibrinolysis in a variety of clinical conditions.",
author = "M. Udvardy and E. Posan and J. H{\'a}rsfalvi and M. Kaplar and P. Batar and I. Altorjay",
year = "1996",
language = "English",
volume = "10",
pages = "27",
journal = "Fibrinolysis and Proteolysis",
issn = "0268-9499",
publisher = "Churchill Livingstone",
number = "SUPPL. 1",

}

TY - JOUR

T1 - 88. in vitro clot-lysis in the presence of cultured human umbilical vein endothelial cells, experiences in diabetes mellitus and liver cirrhosis

AU - Udvardy, M.

AU - Posan, E.

AU - Hársfalvi, J.

AU - Kaplar, M.

AU - Batar, P.

AU - Altorjay, I.

PY - 1996

Y1 - 1996

N2 - In vitro plasma clot-lysis tests might carry some relevant information in vivo fibrinolysis, especially as an indicator of fibrinolytic inhibitors. In vitro clot-lysis experiments, induced by thrombin/tPA mixtures were performed, utilising a microplate light-scattering assessment method. The tests were repeated using the same plasma samples in each patients/controls in a microplate, which was covered by cultured endothelial-cell monolayer (umbilical vein, HUVEC). Clot lysis speed proved to be 1.5-2.0 times slower with HUVEC milieu in the control group (n=79). In insulin dependent diabetes mellitus (n=18) the same inhibition induced by HUVEC was observed, whereas in non-insulin dependent diabetics (n=36) the inhibition proved to be significantly weaker than in the controls. It is probably due to the elevated circulating PAI-1 levels in this type of diabetes. In the cirrhotic patients (p=41) this inhibition was stronger and resulted in a 5-fold reduction of lysis speed. Our results suggest, that cirrhotic plasma is able to accelerate the release of fibrinolytic inhibitors from HUVEC, which phenomenon may also contribute to the complex alterations of fibrinolysis in cirrhotic patients. In vitro plasma clot-lysis, performed in the presence or absence of HUVEC may give further information on fibrinolysis in a variety of clinical conditions.

AB - In vitro plasma clot-lysis tests might carry some relevant information in vivo fibrinolysis, especially as an indicator of fibrinolytic inhibitors. In vitro clot-lysis experiments, induced by thrombin/tPA mixtures were performed, utilising a microplate light-scattering assessment method. The tests were repeated using the same plasma samples in each patients/controls in a microplate, which was covered by cultured endothelial-cell monolayer (umbilical vein, HUVEC). Clot lysis speed proved to be 1.5-2.0 times slower with HUVEC milieu in the control group (n=79). In insulin dependent diabetes mellitus (n=18) the same inhibition induced by HUVEC was observed, whereas in non-insulin dependent diabetics (n=36) the inhibition proved to be significantly weaker than in the controls. It is probably due to the elevated circulating PAI-1 levels in this type of diabetes. In the cirrhotic patients (p=41) this inhibition was stronger and resulted in a 5-fold reduction of lysis speed. Our results suggest, that cirrhotic plasma is able to accelerate the release of fibrinolytic inhibitors from HUVEC, which phenomenon may also contribute to the complex alterations of fibrinolysis in cirrhotic patients. In vitro plasma clot-lysis, performed in the presence or absence of HUVEC may give further information on fibrinolysis in a variety of clinical conditions.

UR - http://www.scopus.com/inward/record.url?scp=33846673359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846673359&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33846673359

VL - 10

SP - 27

JO - Fibrinolysis and Proteolysis

JF - Fibrinolysis and Proteolysis

SN - 0268-9499

IS - SUPPL. 1

ER -